Premium
Determination of medullasin levels for the diagnosis of multiple sclerosis
Author(s) -
Aoki Y.,
Saida T.,
Nakano I.,
Saito T.,
Ikeguchi K.,
Urabe T.,
Nishiguchi E.,
Suzuki H.,
Takahashi K.,
Katsuragi H.,
Mizuno Y.
Publication year - 2000
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1034/j.1600-0404.2000.102004218.x
Subject(s) - multiple sclerosis , immunoassay , medicine , monoclonal antibody , immunology , antibody , pathology , gastroenterology
Objectives – To obtain a simple and reliable clinical parameter for the diagnosis of multiple sclerosis among patients with neurological diseases. Patients and methods – Heparinized peripheral blood was obtained from patients with multiple sclerosis and those with non‐inflammatory neurological diseases and healthy volunteers. A new enzyme immunoassay method determining medullasin levels in human granulocytes was developed by using mouse monoclonal antibody against medullasin. Results – A newly developed enzyme immunoassay method for medullasin can detect as little as 1 ng/ml medullasin and results can be obtained within 2 h. Eighty‐five out of 112 patients with multiple sclerosis (75.8%) showed positive results (above means of normals+2 SD) in the medullasin test, while 15.4% (12/78) of patients with non‐inflammatory neurological disease had positive results. Conclusion – This newly developed enzyme immunoassay method for medullasin is considered to be a useful paraclinical test for the diagnosis of multiple sclerosis.